Thymosin Alpha-1 dosage protocol

What Thymosin Alpha-1 (TA1) Is

Thymosin Alpha-1 (TA1), also known as Thymalfasin, is a synthetic polypeptide (PMID 11381492). It is a peptide hormone naturally produced by the thymus gland (PMID 41373628). TA1 is distinct from beta-thymosins like thymosin beta-4, which primarily sequester G-actin intracellularly (PMID 17468232). Serum levels of TA1 can be lower in individuals with certain pathological conditions compared to healthy individuals (PMID 30063864).

How TA1 is Thought to Work

TA1 is thought to modulate the immune system primarily by augmenting T-cell function (PMID 11381492). It promotes T-cell differentiation and maturation, enhancing thymic output (PMID 41373628, PMID 15546253). TA1 can also modulate dendritic cell and macrophage activity (PMID 41373628). In experimental models, TA1 has been shown to reconstitute immune function in thymectomized animals (PMID 15546253). It exhibits immunomodulatory, anti-inflammatory, and antioxidant properties (PMID 41373628). TA1 can also enhance Th1 immune responses (PMID 15546253).

Laboratory and Animal Studies Report

TA1 has shown efficacy in various experimental models of immune dysfunction. These include infectious diseases such as hepatitis in woodchucks and influenza in mice (animal studies) (PMID 15546253). In cancer models, TA1 demonstrated antitumor effects in melanoma in mice and colorectal carcinoma in rats (animal studies) (PMID 15546253). Recent cell and animal studies indicate that TA1 can reprogram tumor-associated macrophages (TAMs) from an M2 (immunosuppressive) phenotype towards an antitumoral phenotype, thus improving antitumor immunity in the context of oncolytic adenovirus therapy (cell and animal studies) (PMID 39357524).

Human Evidence So Far

TA1 has been evaluated in human clinical trials for various conditions. For chronic hepatitis B, TA1 monotherapy suppressed viral replication in patients (PMID 25640173). In one clinical trial, 9 out of 17 patients treated with TA1 achieved hepatitis B virus (HBV) DNA clearance at six months, compared to 4 out of 15 historical controls (human study) (PMID 11381492). In another human study, 53% of patients had HBV DNA clearance at six months, and in a randomized trial, 40.6% and 25.6% of patients treated with TA1 for 6 and 12 months, respectively, achieved HBV DNA clearance, compared to 9.4% of untreated controls (human studies) (PMID 11381492). Combination therapy of TA1 with interferon alfa-2b (IFN-alpha 2b) showed improved outcomes for chronic hepatitis C. One trial found 71% of patients on combination therapy achieved normal serum ALT levels at six months versus 35% on IFN-alpha 2b alone, with 65% achieving HCV RNA clearance versus 29% on IFN-alpha 2b alone (human study) (PMID 11381492). TA1 also appears to improve vaccine response in the elderly (human studies) (PMID 41373628). Clinical studies suggest that TA1, alone or in combination, may reduce mortality rates in sepsis patients, improve monocyte HLA-DR expression, and decrease the incidence of secondary infection (human studies) (PMID 30063866).

Open Questions and Limitations

Despite promising findings, questions remain regarding the physiological basal levels of TA1 and the most effective dose and treatment schedule (PMID 30063864). For sepsis, the heterogeneous nature of the syndrome makes it challenging to generalize clinical results to all patients, and future trials may benefit from focusing on immunosuppressed individuals (PMID 30063866). Further research is needed to validate the long-term efficacy and safety of TA1 in geriatrics, particularly concerning its potential to slow the aging process (PMID 41373628).

Key Terms Explained

<b>T-cells:</b> A type of white blood cell critical for immune responses, particularly in recognizing and fighting infections and cancer cells.

<b>Thymic involution:</b> The age-related shrinkage of the thymus gland, leading to reduced T-cell production.

<b>HBV DNA clearance:</b> The absence of hepatitis B virus DNA in the blood, indicating a reduction in viral replication.

<b>ALT levels (Alanine Aminotransferase):</b> An enzyme found mostly in the liver; elevated levels can indicate liver damage.

<b>M2 phenotype macrophages:</b> A type of macrophage often associated with immunosuppression and promoting tumor growth in the tumor microenvironment.